公告称，公司于近日收到公司实际控制人、董事长、总裁陆勇家属的通知，被告知其收到启东市监察委员会签发的《留置通知书》，陆勇因江苏半步堂置 业有限公司相关事宜被实施留置，本次留置为陆勇个人事务，与公司无关。 截至本公告披露日，公司未收到相关机关的其他通知。 7月28日晚间，世名科技（300522.SZ）披露关于公司实际控制人、董事长、总裁被采取留置措施的公告。 总市值54亿元的上市公司 资料显示，苏州世名科技股份有限公司成立于2001年12月11日，是国内专业从事色浆、功能添加剂及电脑调色一体化系统研发生产的科技企业。公司2016 年登陆创业板，截至7月28日收盘，世名科技报16.77元/股，总市值约54.08亿元。 公司位于苏州昆山。作为国内纳米着色材料、功能性纳米分散体、特种添加剂供应服务商，世名科技目前有江苏昆山、江苏常熟、湖南岳阳、辽宁盘锦四 大产业基地。 世名科技此前披露的2024年年报显示，2024年公司全年实现营业收入6.97亿元，同比增长2.30%；归属于上市公司股东的净利润为2262万元，同比增长 25.61%。 2025年一季报显示，报告期内营业总收入为1.59亿元，较去年同报告期营业总收入减 ...

【DT新材料】 获悉，近日， 万华化学 发布 2024年投资完成情况及2025 年投资计划的报告。 2024年，公司 计划项目投资和股权投资总额454亿元，实际完成投资总额428.3亿元，涉及聚氨酯、高新能材料项目等。 2025年公司计划项目投资和股权投资总额294.3亿元 ，其中主要项目计划投资252.4亿元。重点建设MDI扩能 一体化配套项目， 加快自主研发的绿色功能添加剂、香兰素、营养品等 一系列营养科技产品的工业化建 设，持续打造公司第二增长曲线，加快 磷酸铁锂、PVDF 等一系列电池材料等项目建设等。 紧接着，万华化学 公示两大化工新材料项目 环境影响报告书征求意见稿，主要是精细化学品。 第一个项目：特种酯HEMA二期技改扩能项目 该项目拟 在现有HEMA装置的基础上进行改扩能，新 增 20000t/a的产能 ，扩能后HEMA最大产能 可达 55000t /a ，HPMA最大产能可达 55000t/a。 据悉，此前，2018年底，万华化学依托乙烯项目的环氧乙烷产品，规划了年产2万吨的高端HEMA项 目，并在2020年下半年建成投产， 产品纯度达到高端标准（98%-99%）。2023年11月， 万华化 ...

Core Viewpoint - *ST Lvkang is facing significant uncertainty regarding its ability to continue operations due to insolvency, while simultaneously engaging in a series of capital actions such as equity transfers that appear to be self-rescue efforts. The question arises whether the company will pursue a backdoor listing or engage in "tri-party transactions" in its capital operations, with the former being potentially more uncertain given the urgency of maintaining its listing status [1] Group 1: Financial Performance and Business Transition - Lvkang Biotech, originally focused on veterinary drug raw materials and probiotics, has seen a decline in performance since its listing in 2017, with a net profit drop of 6.97%, 13.08%, 23.73%, and 24.15% from 2017 to 2020 [2] - In 2021, the company reported a revenue of 363 million yuan, a year-on-year increase of 17.93%, but incurred a net loss of 26.04 million yuan, a decline of 160.28% compared to the previous year [2] - The company entered the photovoltaic film sector in 2022 through acquisitions, leading to a significant stock price increase from around 10 yuan to a peak of 65.9 yuan, representing a more than fivefold increase [2] Group 2: Ongoing Losses and Financial Challenges - Lvkang Biotech has continued to incur losses, with net profits of -122 million yuan, -222 million yuan, and -445 million yuan projected for 2022, 2023, and 2024 respectively, indicating a worsening financial situation [3] - The photovoltaic film business has negatively impacted the company's financial statements due to low gross margins and high financial costs associated with increased bank loans and financing leases [3] - As of December 31, 2024, the company's current liabilities exceeded current assets by over 1 billion yuan, raising significant doubts about its ability to continue as a going concern [4] Group 3: Shareholder Changes and Market Reactions - On April 24, 2025, Lvkang Biotech announced a change in control, with major shareholders transferring shares to Zongteng Network at a price of 13.73 yuan per share, totaling approximately 639.93 million yuan [5] - This transfer will increase Zongteng Network's ownership to 29.99%, surpassing the previous controlling shareholder's stake [5] - The market is speculating whether Zongteng Network's involvement indicates a backdoor listing or a different capital strategy, especially as the company also announced plans to divest its photovoltaic assets [9] Group 4: Strategic Moves and Future Outlook - Lvkang Biotech's recent capital operations, including the divestiture of its photovoltaic film business, may be aimed at clearing obstacles for future transactions [9] - The company signed an asset transfer agreement on April 24, 2025, to sell all assets and liabilities related to its photovoltaic film business to a joint venture established by its shareholders [9] - The potential for a backdoor listing or tri-party transaction remains uncertain, with regulatory hurdles and the urgency of maintaining its listing status complicating the situation [9]

星标 ★ IPO日报 精彩文章第一时间推送 4月22日午间，绿康生化股份有限公司（下称"绿康生化"，SZ002868）披露公告称，因筹划控制权变更，公司股票自4月22日开市起停牌，预计 停牌时间不超过2个交易日。 公告显示，绿康生化于4月21日收到公司控股股东上海康怡投资有限公司、实际控制人赖潭平的通知，其正在筹划股份转让事项，该事项可能涉及 公司控制权变更。本次交易对手方主要从事跨境物流业务。 绿康生化表示，上述事项正在洽谈当中，尚存在重大不确定性。待上述事项确定后，公司将及时发布相关公告并申请公司股票复牌。 4月21日，绿康生化股价涨停，当日公司股价收于涨停价15.25元。 "兽药+光伏胶膜" 据悉，绿康生化起初是一家专注于兽药研发、生产和销售的上市公司。2017年5月，绿康生化在深交所挂牌上市。 绿康生化的跨界光伏之路始于2022年。 由于近几年国内畜牧养殖市场低迷等原因，绿康生化业务经营持续承压。为扭转这一局面，绿康生化自2022年7月宣布，通过6倍溢价收购 江西纬 科新材料科技有限公司（下称"江西纬科"） 切入光伏胶膜行业，交易总对价9500万元。同时，绿康生化宣布全资子公司拟在海宁市黄湾镇投资建 ...